VolitionRX Ltd (NYSEAMERICAN:VNRX) Director Martin Charles Faulkes bought 70,731 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were purchased at an average cost of $3.02 per share, with a total value of $213,607.62. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.
VNRX traded down $0.06 during midday trading on Wednesday, hitting $3.02. The company had a trading volume of 714 shares, compared to its average volume of 85,509. VolitionRX Ltd has a 52 week low of $1.44 and a 52 week high of $3.63.
VolitionRX (NYSEAMERICAN:VNRX) last posted its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12).
Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in VolitionRX in the first quarter valued at $35,000. Renaissance Technologies LLC bought a new stake in VolitionRX in the first quarter valued at $37,000. Charles Schwab Investment Management Inc. bought a new stake in VolitionRX in the first quarter valued at $50,000. BlueCrest Capital Management Ltd bought a new stake in shares of VolitionRX during the first quarter worth about $81,000. Finally, Bank of New York Mellon Corp increased its position in shares of VolitionRX by 179.9% during the fourth quarter. Bank of New York Mellon Corp now owns 28,924 shares of the medical research company’s stock worth $52,000 after acquiring an additional 18,589 shares in the last quarter.
VolitionRX Company Profile
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Featured Article: Fiduciary
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.